Melanocortin based peptide PT-141, or bremelanotide, works on brain receptors to affect sexual desire. Learn how it works, dosing, safety, and FDA status.
A melanocortin based peptide PT-141 is a synthetic peptide that acts on melanocortin receptors in the brain to influence sexual desire rather than blood flow. The prescription version, bremelanotide, is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, while PT-141 sold as a research chemical is not approved for human use. That distinction matters before you read anything else about dosing, results, or where to buy it.
What PT-141 Actually Is
PT-141 is the research code name for bremelanotide, a cyclic peptide derived from melanotan II. Scientists developed it while studying melanocortin analogs for skin pigmentation and noticed consistent effects on sexual desire during early trials.
The peptide binds mainly to the MC4R melanocortin receptor in the brain. That pathway is separate from the nitric oxide pathway used by drugs like sildenafil, which is why PT-141 is usually discussed in terms of desire rather than erection mechanics alone.
Anything sold as a melanocortin-based peptide pt-141 from a research vendor is not the same as the FDA-approved prescription drug. Purity, sterility, and actual peptide content can vary widely between suppliers.
How Melanocortin-Based Peptides Work in the Body
Melanocortin receptors are concentrated in the hypothalamus and limbic system, regions tied to motivation and reward. Activating MC4R appears to amplify sexual desire signaling in the brain instead of relaxing blood vessels.
Because the mechanism is central rather than vascular, researchers have studied PT-141 in people who respond poorly to PDE5 inhibitors. Clinical work has focused on premenopausal women with low sexual desire and on men with erectile dysfunction.
PT-141 is not a hormone. It does not raise testosterone, and it does not function like testosterone replacement therapy.
PT-141 vs. Other Options: A Quick Comparison
Interest in a pt-141 peptide for men has grown partly because approved treatments for low sexual desire in men are scarce. The table below shows how PT-141 compares with other commonly discussed options.
| Option | How it is taken | FDA status | Time to effect | Primary use |
|---|---|---|---|---|
| PT-141 (bremelanotide, Vyleesi) | Subcutaneous injection | Approved by prescription | About 45 minutes | HSDD in premenopausal women |
| Research-grade PT-141 | Injection or nasal spray | Not approved | Poorly documented | Sold for research only |
| Sildenafil (Viagra) | Oral tablet | Approved | 30–60 minutes | Erectile dysfunction |
| Testosterone therapy | Injection, gel, or patch | Approved for hypogonadism | Weeks | Clinically low testosterone |
The FDA-approved form of PT-141 is an injectable prescription for a specific diagnosis. Research products sold online fall into an entirely different regulatory category.
Dosing and Administration in Practice
The approved Vyleesi dose is 1.75 mg injected under the skin of the abdomen or thigh at least 45 minutes before sexual activity. The label limits use to once in 24 hours and no more than eight doses per month.
Any pt-141 peptide dosage chart you find online describes research or anecdotal use, not approved medical guidance. No validated male-specific dosing exists, so numbers circulated on forums should be treated as unverified.
A pt-141 peptide nasal spray is a common research format, but nasal absorption is inconsistent and published pharmacokinetic data is limited. Injection and nasal routes are not interchangeable at the same milligram dose.
Side Effects, Safety, and Legal Status
Commonly reported side effects of bremelanotide include nausea, flushing, headache, and injection-site reactions. A small number of users experience a temporary rise in blood pressure, which is why the prescribing label recommends checking blood pressure before use.
PT-141 is not FDA-approved for human use when sold as a research chemical. Bremelanotide is FDA-approved as Vyleesi only for premenopausal women with hypoactive sexual desire disorder, and it requires a prescription.
Talk with a healthcare professional before using any peptide, especially if you take blood pressure medication, have cardiovascular disease, or are pregnant or breastfeeding.
Where People Look for PT-141 and What to Watch For
Searches for pt-141 peptide near me usually blend two very different things: a prescription from a licensed clinician and an unregulated research vial from an online store. Those are not equivalent products, and the legal and safety implications differ sharply.
If you are pursuing the prescription route, a licensed provider can evaluate whether bremelanotide is appropriate for your situation. If you are reading vendor listings instead, treat marketing claims as unverified until independent testing confirms them.
Look for a certificate of analysis, a named third-party lab, and a stated purity level. None of those guarantees safety, but their absence is a clear red flag.
The Bottom Line
PT-141 is a real, studied melanocortin peptide with one narrow FDA-approved use in premenopausal women with low sexual desire. Everything else sold under that name is a research chemical with no guaranteed identity, dose, or safety profile.
If low sexual desire is affecting your life, a clinician is the right starting point. Self-experimenting with unregulated peptides carries risks that are difficult to quantify.
Frequently Asked Questions
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the research code name for bremelanotide, the active ingredient in the FDA-approved drug Vyleesi. The two names refer to the same molecule, though the approved product and online research vials are not manufactured or regulated the same way.
Is PT-141 FDA-approved?
Bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. PT-141 sold as a research chemical is not FDA-approved for human use, and no approved version exists for men.
How long does PT-141 take to work?
In clinical trials, bremelanotide is injected about 45 minutes before sexual activity, with effects typically reported within an hour. Nasal research products have inconsistent absorption, so timing is far less predictable and dosing is not standardized.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.